Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.13
-0.3450-1.54%
Volume:2.46M
Turnover:53.83M
Market Cap:2.80B
PE:61.78
High:22.67
Open:20.92
Low:20.10
Close:22.47
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:1.42
T/O Rate:3.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:6.98
PE(LYR):-13.85

Loading ...

Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares

Reuters
·
Jan 22

How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake

Simply Wall St.
·
Jan 22

Apellis Valuation Undervalues Empaveli Opportunity in Rare Kidney Disease, BofA Says

MT Newswires Live
·
Jan 22

BofA Securities Upgrades Apellis Pharmaceuticals to Buy From Neutral, $28 Price Target

MT Newswires Live
·
Jan 21

Apellis Pharmaceuticals Shares Add 3.7% Premarket After Bofa Global Research Upgrades to Buy From Neutral

THOMSON REUTERS
·
Jan 21

Apellis Pharmaceuticals Inc : Bofa Global Research Raises to Buy From Neutral

THOMSON REUTERS
·
Jan 21

Apellis Pharmaceuticals Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Jan 21

Apellis upgraded to Buy from Neutral at BofA

TIPRANKS
·
Jan 21

U.S. RESEARCH ROUNDUP-IBM, KLA, WEX

Reuters
·
Jan 21

RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 20

Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases

MT Newswires Live
·
Jan 16

European Commission Approves Aspaveli by Sobi for Treatment of C3G and Primary IC-MPGN

Reuters
·
Jan 16

Apellis CEO Cedric Francois Reports Disposal of Common Shares

Reuters
·
Jan 16

Apellis Pharmaceuticals (APLS) Receives a Buy from Citi

TIPRANKS
·
Jan 15

Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis price target lowered to $35 from $39 at Cantor Fitzgerald

TIPRANKS
·
Jan 13

Wells Fargo Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis falls -17.3%

TIPRANKS
·
Jan 13